Cabergoline, Dopamine and Libido: Why 19-Nor Steroids Kill Sex Drive and How Cabergoline Restores It

Cabergoline and libido are directly linked through dopamine, the neurotransmitter that governs sexual desire, arousal, the capacity for erection and the ability to reach orgasm. When 19-nor steroids like Nandrolone and Trenbolone elevate prolactin through progesterone receptor activation, prolactin suppresses dopaminergic signalling in the brain areas that control sexual behaviour. The result is the progressive loss of libido, erectile dysfunction and anorgasmia that bodybuilders call “Deca dick” or “Tren dick.” This guide explains the full neurochemical pathway from prolactin elevation to sexual dysfunction, how cabergoline reverses it by acting as a dopamine D2 receptor agonist, the dose-response relationship between cabergoline and sexual function, the timeline of recovery after starting treatment, and why supraphysiological testosterone cannot compensate for the dopamine deficit that elevated prolactin creates. Available from Intex Pharma UK, Intex Pharma Cabergoline 0.25mg is the compound that restores the dopamine signal that prolactin has suppressed.

The Dopamine-Prolactin Axis: How These Two Hormones Control Male Sexual Function

Dopamine and prolactin exist in a reciprocal relationship. Dopamine, produced by neurons in the tuberoinfundibular dopaminergic (TIDA) pathway of the hypothalamus, tonically inhibits prolactin secretion from lactotroph cells in the anterior pituitary. When dopamine levels are adequate, prolactin stays low and sexual function is unimpaired. When dopamine activity drops or prolactin is stimulated by an external signal (such as progesterone receptor activation from a 19-nor steroid), prolactin rises and in turn further suppresses dopamine signalling, creating a self-reinforcing cycle of rising prolactin and falling dopamine that progressively degrades sexual function.

The 2024 International Consultation on Sexual Medicine (ICSM) reviewed the evidence on hormonal regulation of male sexual desire and confirmed that prolactin increases dopamine turnover in the nigrostriatal and mesolimbic tracts (brain areas governing reward, motivation and sexual behaviour). Crucially, the consultation found that severely elevated prolactin levels above 35 ng/mL were associated with a more than tenfold increased probability of reporting hypoactive sexual desire. Among a population of 3,714 men consulting for sexual dysfunction, 85% of those with severe hyperprolactinemia reported low libido as their primary complaint. This is not a subtle effect. Elevated prolactin does not mildly reduce libido; it can functionally eliminate it.

The Four Phases of Male Sexual Function and How Prolactin Disrupts Each One

Male sexual function is not a single process. It comprises four distinct phases, each with different neurochemical requirements, and elevated prolactin disrupts each one through a slightly different mechanism. Understanding which phase is impaired helps users recognise prolactin-driven dysfunction before it becomes entrenched.

The Refractory Period: Why Prolactin Is the “Off Switch” for Male Sexuality

The relationship between prolactin and the male refractory period is the key to understanding why 19-nor-driven prolactin elevation is so devastating to sexual function. In a landmark study, Kruger et al. (2003) in the Journal of Endocrinology demonstrated that prolactin acts as a neuroendocrine “off switch” for male sexual behaviour following orgasm. After orgasm, prolactin surges by 300 to 500% above baseline and remains elevated for approximately 60 minutes. During this window, dopamine activity in the mesolimbic and nigrostriatal pathways is suppressed, creating the subjective experience of sexual satiation: the temporary loss of desire, the inability to achieve erection and the sensation that further sexual activity is neither wanted nor possible.

In the same study, when researchers administered cabergoline (0.5mg orally) to healthy men before sexual activity, prolactin levels were pharmacologically suppressed. The results were striking: cabergoline significantly enhanced all parameters of sexual drive, function and orgasm quality compared to placebo. Most notably, the perception of the refractory period was significantly improved, with subjects reporting faster return of sexual desire and capacity for arousal after orgasm. When the prolactin-stimulating drug protirelin was co-administered with cabergoline to reverse the prolactin suppression, the sexual enhancement was completely abolished, confirming that the effects were mediated through prolactin modulation rather than any non-specific dopaminergic stimulation.

Now apply this physiology to a bodybuilder running 400mg of Nandrolone Decanoate per week. Progesterone receptor activation from Nandrolone chronically stimulates prolactin secretion, keeping baseline prolactin elevated well above the normal range. The user is effectively living in a permanent refractory state: the same neurochemical environment that normally exists for 60 minutes after orgasm persists 24 hours a day, 7 days a week, for the entire duration of the cycle. Desire is suppressed. Arousal is impaired. Orgasm is delayed or impossible. No amount of testosterone can override this because testosterone and dopamine act on different receptors in different brain circuits. Testosterone provides the androgenic substrate for sexual function; dopamine provides the motivational and functional signal. Without dopamine, the substrate is inert.

Why More Testosterone Does Not Fix Prolactin-Driven Sexual Dysfunction

This is the most counterintuitive aspect of 19-nor sexual dysfunction for bodybuilders: a user injecting 500mg of testosterone per week with a serum level of 3,000+ ng/dL can have zero libido and complete erectile dysfunction. The instinct is to assume that testosterone equals sex drive, and therefore more testosterone should mean more sex drive. This assumption is wrong because it conflates the hormonal substrate with the neurochemical signal.

Testosterone acts primarily through androgen receptors to establish the baseline capacity for sexual function. Below a certain threshold (approximately 300 ng/dL), testosterone deficiency directly causes hypoactive sexual desire. Above this threshold, further increases in testosterone produce diminishing returns for libido because the androgen receptors are already saturated. At supraphysiological levels, additional testosterone does not create additional sexual drive because the bottleneck has shifted from the androgen axis to the dopamine axis.

Dopamine, conversely, acts in the mesolimbic reward system and the medial preoptic area to provide the motivational drive for sexual activity, the central erectile signal and the orgasm threshold modulation. When prolactin suppresses dopamine in these circuits, the sexual function machinery is neurochemically disabled at the central nervous system level regardless of how much androgen receptor stimulation is occurring in the periphery. Injecting more Intex Pharma Testosterone Enanthate 300mg will not restore dopamine activity. Only a dopamine agonist will restore dopamine activity. Cabergoline acts directly on D2 receptors in the pituitary to suppress prolactin and in the mesolimbic system to enhance dopaminergic tone, addressing the actual cause of the dysfunction.

How Cabergoline Restores Libido: The D2 Receptor Mechanism

Cabergoline is an ergoline-derived dopamine D2 receptor agonist with an elimination half-life of 63 to 69 hours. It works through two concurrent mechanisms that together restore the dopamine-prolactin balance required for normal sexual function.

Mechanism 1: Prolactin suppression. By binding to D2 receptors on lactotroph cells in the anterior pituitary, cabergoline directly inhibits prolactin secretion. D2 receptor activation in lactotrophs triggers a cascade that suppresses adenylyl cyclase, reduces intracellular cAMP and inhibits the transcription and secretion of prolactin. De Rosa et al. (1998) in the European Journal of Endocrinology demonstrated that cabergoline normalised prolactin levels and restored gonadal and sexual function in hyperprolactinemic males more rapidly and completely than bromocriptine, with all patients showing improvement in libido and sexual potency within the first months of treatment. Prolactin levels dropped and sexual function improved in parallel, confirming the causal relationship.

Mechanism 2: Direct dopaminergic stimulation. Cabergoline does not only work by lowering prolactin; it also directly stimulates D2 receptors in the mesolimbic reward pathway and the nigrostriatal system. This direct dopaminergic effect contributes to the subjective enhancement of sexual desire, motivation, mood and orgasm quality that users report beyond what would be expected from prolactin normalisation alone. This is also why cabergoline at excessive doses can produce compulsive behaviours (discussed below): the direct dopaminergic stimulation can overshoot the therapeutic range.

Timeline: How Quickly Libido Returns After Starting Cabergoline

The speed of recovery is why preventative cabergoline dosing is so strongly recommended on Trenbolone cycles. A user who starts cabergoline alongside Trenbolone from week 1 never enters the prolactin-driven dysfunction state. A user who waits 6 weeks for symptoms to develop, then starts cabergoline, must endure 2 to 4 additional weeks of recovery after starting treatment. That is 8 to 10 weeks of a 12-week cycle with impaired sexual function, which is most of the cycle. For the preventative dosing protocols by compound, see the complete guide on cabergoline dosing for Deca and Trenbolone.

The Dose-Response Danger: When Cabergoline Enhances Libido Too Much

There is a therapeutic window for cabergoline’s effects on libido, and exceeding it produces problems of its own. At therapeutic doses (0.25 to 0.5mg twice weekly for bodybuilding prolactin management), cabergoline restores normal dopaminergic tone: libido returns to baseline, sexual function normalises and mood improves. At excessive doses, or in individuals who are particularly sensitive to dopaminergic stimulation, cabergoline can push dopamine activity above the normal range, producing hypersexuality, compulsive sexual behaviour, impulsive decision-making and in clinical populations (particularly Parkinson’s disease patients on high-dose dopamine agonists), pathological gambling, compulsive spending and other impulse control disorders.

Bodybuilding forums often celebrate the “enhanced libido” from cabergoline without acknowledging that this enhancement has a ceiling beyond which it becomes compulsive rather than pleasurable. Prolactin that is driven below the reference range (not just normalised but suppressed to near zero) removes the natural satiation signal after orgasm entirely, which sounds appealing until the user realises they cannot stop thinking about sex, their decision-making is impaired by constant sexual preoccupation and their behaviour is becoming increasingly reckless. The goal of cabergoline dosing is normalisation of prolactin and restoration of function, not suppression of prolactin to zero and the creation of a dopamine-driven compulsive state.

Cabergoline and PDE5 Inhibitors: Do You Need Both?

Some users running 19-nor compounds attempt to solve erectile dysfunction with PDE5 inhibitors (Tadalafil/Cialis, Sildenafil/Viagra) before addressing prolactin. PDE5 inhibitors work by enhancing nitric oxide signalling in the corpus cavernosum, improving blood flow to achieve and maintain an erection. They address the peripheral vascular component of erection but do not address the central dopaminergic component: desire, arousal initiation and orgasm.

A user with prolactin-driven sexual dysfunction who takes Cialis will likely achieve a partial erection because the peripheral blood flow mechanism is enhanced, but the erection will feel disconnected from desire (because desire requires dopamine that prolactin has suppressed), and orgasm will remain delayed or impossible (because orgasm requires dopaminergic threshold activation). The user can mechanically perform but does not want to and cannot finish. This produces a frustrating, unsatisfying sexual experience that PDE5 inhibitors alone cannot fix.

Cabergoline addresses the central cause. Once prolactin is normalised and dopaminergic tone is restored, the desire returns, the central arousal signal is re-established and orgasm becomes achievable again. At that point, if residual erectile difficulty exists (from other causes such as cardiovascular health, anxiety or oestrogen imbalance), a PDE5 inhibitor can address the remaining peripheral component. The correct order is always: fix prolactin first, then add PDE5 inhibitor if needed. Never the reverse. For general pre-cycle bloodwork guidance, follow the linked guide.

Cabergoline, Dopamine and Libido: Frequently Asked Questions